Jove
Visualize
Contact Us

Related Experiment Videos

Clinical constructs and therapeutic discovery.

William T Carpenter1

  • 1University of Maryland Baltimore, Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228, USA. wcarpent@mprc.umaryland.edu

Schizophrenia Research
|November 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes.

Advances in neurobiology·2024
Same author

Time to Stop Using the Term Relapse in Schizophrenia Clinical Trials.

Schizophrenia bulletin open·2024
Same author

Psychosis superspectrum II: neurobiology, treatment, and implications.

Molecular psychiatry·2024
Same author

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.

Schizophrenia research·2023
Same author

Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.

The lancet. Psychiatry·2023
Same author

Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.

Schizophrenia bulletin·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Schizophrenia treatment paradigms are shifting. Current antipsychotic drugs targeting psychosis are insufficient, highlighting the need for novel therapies addressing cognitive and negative symptoms for improved patient outcomes.

Area of Science:

  • Psychiatry and Neuroscience
  • Clinical Psychology
  • Pharmacology

Background:

  • The traditional view of schizophrenia as a single disease entity has focused on psychotic symptoms for a century.
  • This focus has led to the development of dopamine antagonist antipsychotic drugs, neglecting other aspects of the disorder.
  • Existing treatments primarily address reality distortion and thought disorders, leaving other symptoms unaddressed.

Purpose of the Study:

  • To propose an alternative paradigm for understanding schizophrenia based on distinct psychopathological domains.
  • To highlight the limitations of current antipsychotic medications in addressing nonpsychotic symptoms.
  • To identify unmet treatment needs and guide future drug discovery for schizophrenia.

Main Methods:

Related Experiment Videos

  • Review of existing literature on schizophrenia classification and psychopathology.
  • Analysis of the relationship between different symptom domains (reality distortion, disorganization, negative pathology, cognition) and functional outcomes.
  • Evaluation of the efficacy of current antipsychotic drug classes.

    • Main Results:

    • The domains of psychopathology paradigm emphasizes the relative independence of reality distortion, disorganization, negative symptoms, and cognitive impairments.
    • Impaired cognition and negative symptoms are strongly correlated with poor functional outcomes in schizophrenia.
    • Current antipsychotic drugs demonstrate limited efficacy in treating these nonpsychotic pathologies.

    Conclusions:

    • A paradigm shift towards understanding schizophrenia through its distinct psychopathological domains is necessary.
    • Novel therapeutic pathways targeting cognitive and negative symptoms are crucial for improving functional outcomes.
    • Addressing these unmet needs represents a significant opportunity for drug discovery in schizophrenia treatment.